Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: A case report

Acta Urologica Japonica

Volumn 56, Issue 1, 2010, Pages 49-54

  Segawa, Naoki ^a   Inamoto, Teruo ^a   Ibuki, Naokazu ^a   Mizutani, Yoichi ^a   Azuma, Haruhito ^a   Tsuji, Motomu ^a   Katsuoka, Yoji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Neuroendocrine carcinoma; Neuroendocrine differentiation; Prostate

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ENOLASE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CASE REPORT; CELL DIFFERENTIATION; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIFFERENTIATION; HUMANS; LEUPROLIDE; MALE; PHOSPHOPYRUVATE HYDRATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77349124926     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Oesterling JE, Hauzeur CG and Farrow GM: Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 147: 804-807, 1992
2. Sobin LH and Wittekind CH: TNM Classification of Malignant Tumors, 6th ed, Wiley-Liss, New York, 2002
3. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Int J Clin Oncol 9 Supp III: 1-82, 2004
4. Di Sant' Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Cancer 70: 254-267, 1992
5. Bostwick DG, Grignon DJ, Hammond EH, et al.: Prognostic factors in prostate cancer College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124: 995-1000, 2000
6. Japanese source
7. Yashi M, Muraishi O and Tokue A: Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide. BJU Int 86: 1091-1092, 2000
8. Japanese source
9. Spiess PE, Pettaway CA, Vakar-Lopez, et al.: Treatment outcome of small cell carcinoma of the prostate. Cancer 110: 1729-1737, 2007
10. Japanese source
11. Japanese source
12. Chong S, Lee KS, Kim BT, et al.: Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol 188: 1223-1231, 2007
13. Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotccan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 1992
14. Kudoh S, Takeda M, Masuda N, et al.: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84: 203-207, 1993
15. Katou M, Soga N, Onishi T, et al.: Small cell carcinoma of the prostate treated with amrubicin. Int J Clin Oncol 13: 169-172, 2008
16. Abbas F, Civantos F, Benedetto PJ, et al.: Small cell carcinoma of the bladder and prostate. Urology 46: 617-630, 1995
17. Japanese source
18. Japanese source
19. Miyoshi Y, Uemura H, Kitami K, et al.: Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 88: 982-983, 2001
20. Japanese source
21. Hanazawa K, Higashi N, Kawachi Y, et al.: Small cell carcinoma of the prostate with hypercalcemia. Int J Urol 12: 108-110, 2005
22. Japanese source
23. Japanese source
24. Japanese source
25. Japanese source
26. Sciarra A, Cardi A, Dattilo C, et al.: New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 60: 462-470, 2006